Funding renewal supports advanced therapies sector

An £80 million award granted under Innovate UK’s £1.6bn Catapult programme, will help to drive the Cell and Gene Therapy Catapult’s (CGT Catapult) activities in continuing to build the UK’s thriving advanced therapies industry until March 2028. The figure represents a 35% increase compared to the previous five years and will enable the Catapults to generate more impact, fostering enhanced strategic coherence and ensuring optimal value for the taxpayer.

Operating in four locations across the UK, CGT Catapult works with industry, academia and the healthcare system, helping researchers to commercialise their discoveries, industry to develop efficiency in manufacture of advanced therapies and the NHS to effectively deliver these new modalities. Along with provision of upskilling and training for the existing and future workforce, the work of the CGT Catapult has impacted all stages of the advanced therapies lifecycle.

Matthew Durdy, Chief Executive of the CGT Catapult, said: “We would like to thank our colleagues at Innovate UK for their support and the people of the CGT Catapult for their relentless commitment, as well as all of our collaborators who make our projects and delivery possible. This funding will enable us to continue our work with the advanced therapies sector, helping the industry grow, creating high productivity employment and ultimately helping more patients receive the life-changing cell and gene therapies they need.”

More information online